You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The updated guidelines now also highlight the use of PCR and next-generation sequencing to determine microsatellite instability.
GenPro will use its EpiMarker machine-learning platform to identify a network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of drug response.
Paige said that the regulatory clearance paves the way for the in vitro diagnostic use of FullFocus with additional IVD whole slide imaging scanners.
The facility, which plans to launch an MRM assay for HER2 as its initial test, is one of the few clinical labs to focus primarily on targeted protein mass spec.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
The classifiers are considered reasonable and necessary if the patient can tolerate chemotherapy and it's being considered as a treatment for the patient.
The initiative will offer a liquid biopsy tool that only requires a blood draw for cancer treatment selection instead of a tissue biopsy.
The firm said the New York State approval for the two tests comes soon after it launched Sema4 Signal, a family of precision oncology products and services.
The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.
The firm said it anticipates that proceeds from the financing will support a study of its technology for NASH patients, which may enable a premarket approval.
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
BTIG put a $20 target price on Genetron's shares, while Canaccord Genuity is targeting $19 per share for the Chinese genomics and cancer diagnostics firm.
The firm said it will use the new capital to further develop cancer pathology workflows and create custom diagnostic and clinical trial solutions.
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.
Four diagnostic firms have gone public so far this year, with three of the companies based in China but filing for US initial public offerings.